# US 9,102,912 B2 · Cellular permissivity factor for viruses and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,102,912 B2
- Document ID: US9102912B2
- Status: Granted
- Kind: B2
- Application number: 13/940,317
- Filed: 2013-07-12
- Published: 2014-05-22
- Granted: 2015-08-11
- Earliest claimed: 2004-04-23
- Assignees: Zoetis Services LLC
- Applicants: Zoetis Services LLC
- Inventors: Jay Gregory Calvert; Shelly Shields; David E. Slade; Siao-Kun Welch
- Web page: https://patentgrep.com/patent/US9102912B2

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 5/0686: {Kidney cells}
- C12N 5/0688: {Cells from the lungs or the respiratory tract}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2510/00: Genetically modified cells
- C12N 2510/02: Cells for production
- C12N 2710/12051: Methods of production or purification of viral material
- C12N 2770/10051: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus.

## Claims

### Claim 1

A method of facilitating production of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) from a culture of vertebrate cells, comprising the steps of:
(a) providing a recombinant vertebrate cell transfected with an exogenous polynucleotide that encodes a polypeptide having a transmembrane domain and at least 85% sequence identity to SEQ ID NO:46, so that expression of CD163 polypeptide in said cell is increased;
(b) contacting a culture of said cell with PRRSV virus under conditions which permit infection of the cells and growth of the virus; and
(c) recovering virus from said culture.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell was previously PRRSV permissive and is rendered more PRRSV permissive.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cell did not previously express a CD163 polypeptide and is induced to express CD163.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cell is selected from the group consisting of baby hamster kidney cells (BHK21), porcine kidney cells, feline kidney cells, avian cells, and swine testicular cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the PRRSV is of the European genotype.

### Claim 6 (depends on 1)

The method of claim 1, wherein the PRRSV is of the North American genotype.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polynucleotide encodes a polypeptide having a transmembrane domain and at least 90% sequence identity to SEQ ID NO:46.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polynucleotide encodes a polypeptide having a transmembrane domain and at least 95% sequence identity to SEQ ID NO:46.

### Claim 9 (depends on 1)

The method of claim 1, wherein the polynucleotide encodes a polypeptide having a transmembrane domain and at least 99% sequence identity to SEQ ID NO:46.

### Claim 10 (depends on 1)

The method of claim 1, further comprising the step of producing a vaccine from the recovered virus.